Outcome of the Board Meeting held on 13th November, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited standalone financial results for the half-year ended September 30, 2025. Revenue from operations rose to ₹2,554.60 lakhs from ₹2,179.78 lakhs in H1 FY25, a growth of about 17%. Profit after tax jumped sharply to ₹44.91 lakhs from ₹17.29 lakhs, with basic EPS improving to ₹0.60 from ₹0.23. Total expenses grew modestly while finance costs declined meaningfully from ₹110.09 lakhs to ₹80.85 lakhs, reflecting a reduction in long-term borrowings (from ₹228.35 lakhs to ₹77.16 lakhs). Statutory auditor A Y & Company issued a clean limited review report with no qualifications or emphasis of matter, and there were no pending investor complaints.
Sharp PAT growth and lower finance costs are positive for shareholders, though the bottom-line jump was largely aided by a lower tax outflow rather than a meaningful expansion in operating margins. The stock may see a mildly positive reaction given the strong earnings print and improving debt profile.